Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease

New England Journal of Medicine

Volumn 346, Issue 23, 2002, Pages 1800-1806

  Gaspoz, Jean Michel ^a   Coxson, Pamela G ^b   Goldman, Paula A ^c   Williams, Lawrence W ^c   Kuntz, Karen M ^c   Myriam Hunink, M G ^c,d   Goldman, Lee ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ADULT; AGED; ARTICLE; COMPUTER SIMULATION; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG MIXTURE; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SECONDARY PREVENTION; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ASPIRIN; COMPUTER SIMULATION; CORONARY DISEASE; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG THERAPY, COMBINATION; HUMANS; MIDDLE AGED; MODELS, ECONOMETRIC; PLATELET AGGREGATION INHIBITORS; QUALITY-ADJUSTED LIFE YEARS; TICLOPIDINE;

EID: 0037030666     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200206063462309     Document Type: Article

References (41)

1. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
2. Secondary prevention of vascular disease by prolonged antiplatelet treatment
3. Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: A propensity analysis
4. Aspirin as an antiplatelet drug
5. Aspirin
6. A hearty endorsement for aspirin
7. Aspirin as a therapeutic agent in cardiovascular disease: A statement for healthcare professionals from the American Heart Association
8. Antithrombotic agents in coronary artery disease
9. Treatment and outcomes of acute myocardial infarction among patients of cardiologists and generalist physicians
10. The Cooperative Cardiovascular Project in Oklahoma
11. Aspirin for secondary prevention after acute myocardial infarction in the elderly: Prescribed use and outcomes
12. Aspirin in the treatment of acute myocardial infarction in elderly Medicare beneficiaries: Patterns of use and outcomes
13. Quality of medical care delivered to Medicare beneficiaries: A profile at state and national levels
14. Aspirin use is low among United States outpatients with coronary artery disease
15. Aspirin use among adults with diabetes: Estimates from the Third National Health and Nutrition Examination Survey
16. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
17. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
18. Forecasting coronary heart disease incidence, mortality, and cost: The Coronary Heart Disease Policy Model
19. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease
20. The recent decline in mortality from coronary heart disease, 1980-1990: The effect of secular trends in risk factors and treatment
21. The cost-effectiveness of dietary and pharmacologic therapy for cholesterol reduction in adults
22. Health and economic benefits of increased beta-blocker use following myocardial infarction
23. The effect of risk factor reductions between 1981 and 1990 on coronary heart disease incidence, prevalence, mortality and cost
24. A comparison of economic modeling and clinical trials in the economic evaluation of cholesterol-modifying pharmacotherapy
25. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
26. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease
27. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels
28. The Beaver Dam Health Outcomes Study: Initial catalog of health-state quality factors
29. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: An overview of randomized trials
30. Incidence rates of stroke in the eighties: The end of the decline in stroke?
31. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study
32. Cost-effectiveness of misoprostol for prophylaxis against nonsteroidal anti-inflammatory drug-induced gastroin-testinal tract bleeding
33. Cost-effectiveness of ticlopidine in preventing stroke in high-risk patients
34. The economic impact of stroke
35. Thrombotic thrombocytopenic purpura associated with clopidogrel
36. Clopidogrel and thrombotic thrombocytopenic purpura
37. Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack
38. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2
39. On jumbo and junkie trials: A fumbled affair, a jungle, or the ultimate solution?
40. Therapeutic benefit: Aspirin revisited in light of the introduction of clopidogrel